Inhibition of TRF1 Telomere Protein Impairs Tumor Initiation and Progression in Glioblastoma Mouse Models and Patient-Derived Xenografts.

Glioblastoma multiforme (GBM) is a deadly and common brain tumor. Poor prognosis is linked to high proliferation and cell heterogeneity, including glioma stem cells (GSCs). Telomere genes are frequently mutated. The telomere binding protein TRF1 is essential for telomere protection, and for adult an...

Descripción completa

Detalles Bibliográficos
Autores: Bejarano, Leire, Schuhmacher, Alberto J, Méndez, Marinela, Megías, Diego, Blanco-Aparicio, Carmen, Martinez, Sonia, Pastor Fernandez, Joaquin, Squatrito, Massimo, Blasco, MA
Tipo de recurso: artículo
Fecha de publicación:2017
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/19109
Acceso en línea:http://hdl.handle.net/20.500.12105/19109
Access Level:acceso abierto
Palabra clave:Disease Models, Animal
Animals
Brain Neoplasms
Cell Line, Tumor
Disease Progression
Gene Expression Regulation, Neoplastic
Glioblastoma
Humans
Mice, Knockout
Mice, Nude
Neoplastic Stem Cells
RNA Interference
Telomere
Telomeric Repeat Binding Protein 1
Transplantation, Heterologous
Descripción
Sumario:Glioblastoma multiforme (GBM) is a deadly and common brain tumor. Poor prognosis is linked to high proliferation and cell heterogeneity, including glioma stem cells (GSCs). Telomere genes are frequently mutated. The telomere binding protein TRF1 is essential for telomere protection, and for adult and pluripotent stem cells. Here, we find TRF1 upregulation in mouse and human GBM. Brain-specific Trf1 genetic deletion in GBM mouse models inhibited GBM initiation and progression, increasing survival. Trf1 deletion increased telomeric DNA damage and reduced proliferation and stemness. TRF1 chemical inhibitors mimicked these effects in human GBM cells and also blocked tumor sphere formation and tumor growth in xenografts from patient-derived primary GSCs. Thus, targeting telomeres throughout TRF1 inhibition is an effective therapeutic strategy for GBM.